Clifford A. Hudis, MD, FACP, on Enzalutamide in Androgen Receptor–Positive, Triple-Negative Breast Cancer

2014 San Antonio Breast Cancer Symposium

Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract P5-19-09, “Stage 1 results from MDV3100-11: A two-stage study of enzalutamide, an androgen receptor inhibitor, in advanced androgen receptor–positive triple-negative breast cancer,” presented by Tiffany A. Traina, MD.

Matthew J. Ellis, MD, on Endocrine Therapy–Resistant Breast Cancer

Matthew J. Ellis, MD, PhD, of the Baylor College of Medicine, offers a brief synopsis of his plenary lecture, "Genome-Directed Therapeutics for Endocrine Therapy–Resistant Estrogen Receptor–Positive Breast Cancer."

Breast Cancer

Hope S. Rugo, MD

Apr

Today In Oncology

Clifford A. Hudis, MD, FACP, on Enzalutamide in Androgen Receptor–Positive, Triple-Negative Breast Cancer

Related Videos

Matthew J. Ellis, MD, on Endocrine Therapy–Resistant Breast Cancer

Hope S. Rugo, MD, on Dietary Intervention as Adjuvant Breast Cancer Therapy

Ann H. Partridge, MD, MPH, on Patient-Reported Outcomes From the SOFT Trial

Harry D. Bear, MD, PhD, on the NSABP B-51/RTOG 1304 Trial

Harry D. Bear, MD, PhD, on the NSABP B-40 Study in HER2-Negative Breast Cancer

How Cannabis Use May Be Accelerating Breast and Testicular Cancer Rates in AYAs

Japanese Study Looks at Rates of Cancer Therapy–Related AML

Researchers Identify Blood-Based Biomarker for Cancer Risk in People With Lynch Syndrome

Final Report on Pralsetinib in Advanced RET Fusion–Positive NSCLC

New ASH HematOmics Program Offers Blood Cancer Data Integration Tool to Accelerate Research